# The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

> **NCT03247140** · PHASE1 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Hypertension With Dyslipidemia

## Interventions

- **DRUG:** JLP-1401
- **DRUG:** Telmisartan/Amlodipine, Rosuvastatin

## Key facts

- **NCT ID:** NCT03247140
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-10
- **Primary completion:** 2017-08-07
- **Final completion:** 2017-11-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03247140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03247140, "The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03247140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*